| 10 |
2020.08.20 |
Additional Listing(주식매수선택권행사) |
Aptabio Therapeutics Inc. |
| 9 |
2020.08.03 |
Material Management Information related to Judgment of Investment(당뇨병성 신증 치료제 APX-115의 유럽 임상 2상 시험 계획(IND) 승인) |
Aptabio Therapeutics Inc. |
| 8 |
2020.06.19 |
Other Management Information(Obtainment of Patent)(Voluntary Disclosure)(3-페닐-4-프로필-1-(피리딘-2-일)-1H-피라졸-5-올 염산염의 신규 결정형 고체화합물) |
Aptabio Therapeutics Inc. |
| 7 |
2020.06.12 |
Material Management Information related to Judgment of Investment(당뇨병성 신증 치료제 APX-115의 유럽 임상 2상 시험 계획(IND) 승인) |
Aptabio Therapeutics Inc. |
| 6 |
2020.06.10 |
Material Management Information related to Judgment of Investment(당뇨병성 신증 치료제 APX-115의 유럽 임상 2상 시험 계획(IND) 승인) |
Aptabio Therapeutics Inc. |
| 5 |
2020.06.04 |
Other Management Information(Obtainment of Patent)(Voluntary Disclosure)(간질환 치료제) |
Aptabio Therapeutics Inc. |
| 4 |
2020.05.20 |
Material Management Information related to Judgment of Investment(당뇨병성 신증 치료제 APX-115의 유럽 임상 2상 시험 계획(IND) 승인) |
Aptabio Therapeutics Inc. |
| 3 |
2020.04.28 |
Other Management Information(Obtainment of Patent)(Voluntary Disclosure)(신증 진단용 마커로서의 SH3YL1의 용도) |
Aptabio Therapeutics Inc. |
| 2 |
2020.04.08 |
Additional Listing(주식매수선택권행사) |
Aptabio Therapeutics Inc. |
| 1 |
2020.04.02 |
Other Management Information(Obtainment of Patent)(Voluntary Disclosure) |
Aptabio Therapeutics Inc. |
